Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 3

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 3
---
 the Common Warrants or the Placement Agent Warrants will be exercised. We have agreed to bear all of the expenses incurred in connection with the registration of the shares underlying the Common Warrants and the Placement Agent Warrants. The Selling Stockholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of the shares underlying the Common Warrants and the Placement Agent Warrants. See the section entitled, “ Selling Stockholders” for additional information regarding the Selling Stockholders. We are registering the shares underlying the Common Warrants and the Placement Agent Warrants on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of the shares of common stock by the Selling Stockholders in the offering described in this prospectus. However, we will receive aggregate proceeds of up to approximately (i) $1,575,234 from the cash exercise of the January 2025 Common Warrants; (ii) $887,065 from the cash exercise of the February 2025 Warrants; (iii) $97,804 from the cash exercise of the January 2025 Placement Agent Warrants; and (iv) $100,794 from the cash exercise of the February 2025 Placement Agent Warrants. See “ Use of Proceeds.” We are an “emerging growth company” and a “smaller reporting company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and have elected to comply with certain reduced public company reporting requirements. See “ Summary—Implications of Being an Emerging Growth Company and Smaller Reporting Company.” Our common stock is listed on The Nasdaq Capital Market under the symbol “SXTP.” The closing price of our common stock on March 26, 2025 as reported by The Nasdaq Capital Market, was $1.88. There is no established trading market for the Common Warrants and the Placement Agent Warrants and we do not intend to list the Common Warrants and the Placement Agent Warrants on any securities exchange or nationally recognized trading system. On February 24, 2025, we effected a 1-for-5 reverse stock split (the “Reverse Split”) pursuant to which every five shares of our issued and outstanding shares of common stock were combined to one share of common stock. The Split had no impact on the par value of our shares of common stock or the authorized